Sirolimus for brainstem cavernoma bleeding
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if sirolimus, a medicine that may help reduce abnormal blood vessels, can prevent another brain bleed in people who recently had a bleed from a brainstem cavernoma. You would receive either sirolimus or a placebo to see if it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You had your first-ever brain bleed from a brainstem cavernoma within the last 6 months.
- You have exactly one brainstem cavernoma (not multiple).
- You do not have cancer, a serious infection, or uncontrolled diabetes.
- You are not pregnant, breastfeeding, or allergic to sirolimus or starch.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether sirolimus, a medication that may slow blood vessel changes, can help people with a condition called vertebrobasilar dolichoectasia (VBD), where a major artery in the brain becomes enlarged and twisted. If you have had symptoms or a stroke related to VBD, this study might offer a new treatment option.
This trial tests a new type of stent coated with a medicine to treat narrowed brain arteries. It may help reduce the risk of future strokes compared to standard treatment.
This trial studies how the medicine sirolimus affects children’s response to routine vaccines during treatment for kaposiform hemangioendothelioma (KHE). It compares vaccinated KHE patients taking sirolimus with healthy children getting the same vaccines.
This trial studies whether sirolimus (Rapamune®) can reduce problems from severe arteriovenous malformations (tangled blood vessel connections). It may help shrink the abnormal vessels or improve symptoms, by testing the medicine in people with certain AVM types.
This Phase 2 study tests whether sirolimus, a medicine that changes immune and growth signals, can change what’s happening inside the tissue of unruptured brain aneurysms after a procedure. Researchers hope these molecular changes may help understand how to improve aneurysm outcomes.
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
Hear when a new Intracerebral Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.